Hypertension and medical expenditure in the Japanese population: Review of prospective studies.

Hypertension is a major determinant of health and is likely to have an effect on medical economics. The economic burden due to hypertension may be attributable not only to antihypertensive medication but also to the very expensive procedures required for cases of cardiovascular disease that occur more frequently in hypertensive compared with normotensive individuals. The objective of this article was to review articles published on prospective cohort studies that measured medical expenditure attributable to hypertension in community-dwelling populations in Japan. Many medical services in these populations are provided under the medical insurance system that requires the enrolment of all Japanese residents. Personal medical expenditure attributable to hypertension increases with worsening severity of the condition. Medical expenditure was increased further in cases of hypertensive patients who have another concomitant cardiovascular risk factor. In particular, hypertension, especially moderate-to-severe untreated hypertension, increases the risk of long-term hospitalization resulting in considerably higher medical expenditure, compared with non-hospitalized cases. Therefore, assuming that the use of antihypertensive medication is essential for hypertensive patients to prevent serious vascular diseases, a cost-effective high-risk strategy needs to be considered to reduce both ill-health and the economic burden due to hypertension. However, from a population perspective, medical expenditure attributable to hypertension comes mainly from pre-to-mild hypertension. Therefore, there is also a need to consider a population strategy that aims to shift the entire population to lower levels of blood pressure.

[1]  Gretchen A. Stevens,et al.  The Age-Specific Quantitative Effects of Metabolic Risk Factors on Cardiovascular Diseases and Diabetes: A Pooled Analysis , 2013, PloS one.

[2]  S. Yasumura,et al.  Treated and untreated hypertension, hospitalization, and medical expenditure: an epidemiological study in 314 622 beneficiaries of the medical insurance system in Japan , 2013, Journal of hypertension.

[3]  F. Irie,et al.  Influence of Smoking Combined with Another Risk Factor on the Risk of Mortality from Coronary Heart Disease and Stroke: Pooled Analysis of 10 Japanese Cohort Studies , 2012, Cerebrovascular Diseases.

[4]  H. Ueshima,et al.  Medical expenditures of men with hypertension and/or a smoking habit: a 10-year follow-up study of National Health Insurance in Shiga, Japan , 2010, Hypertension Research.

[5]  F. Irie,et al.  Age-Stratified Analysis of the Impact of Hypertension on National Health Insurance Medical Expenditures in Ibaraki, Japan , 2010, Journal of epidemiology.

[6]  Sai T. Moturu,et al.  Predictive risk modelling for forecasting high-cost patients: a real-world application using Medicaid data , 2010 .

[7]  Masahiro Yoshida,et al.  Health insurance and payment systems for severe acute pancreatitis , 2010, Journal of hepato-biliary-pancreatic sciences.

[8]  A. Rodgers,et al.  Global burden of blood-pressure-related disease, 2001 , 2008, The Lancet.

[9]  Piotr Ponikowski,et al.  2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). , 2007, European heart journal.

[10]  S. Kuriyama,et al.  The joint impact of cardiovascular risk factors upon medical costs. , 2007, Preventive medicine.

[11]  H. Ueshima,et al.  Medical costs of patients with hypertension and/or diabetes: a 10-year follow-up study of National Health Insurance in Shiga, Japan , 2006, Journal of hypertension.

[12]  H. Ueshima,et al.  Impact of Hypertension on Medical Economics: A 10-Year Follow-Up Study of National Health Insurance in Shiga, Japan , 2005, Hypertension Research.

[13]  Shinichi Okamura,et al.  Case-mix payment in Japanese medical care. , 2005, Health policy.

[14]  Daniel W. Jones,et al.  The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. , 2003, JAMA.

[15]  B. Ludvik,et al.  Effect of Obesity on Insulin Resistance in Normal Subjects and Patients With NIDDM , 1995, Diabetes.

[16]  S. Haffner,et al.  Prospective analysis of the insulin-resistance syndrome (syndrome X). , 1992, Diabetes.

[17]  E. Bonora,et al.  Risk factors for coronary artery disease in healthy persons with hyperinsulinemia and normal glucose tolerance. , 1989, The New England journal of medicine.

[18]  G Rose,et al.  Sick individuals and sick populations. , 1985, International journal of epidemiology.

[19]  J. Hirsch,et al.  Adipose-cell size and immunoreactive insulin levels in obese and normal-weight adults. , 1972, Lancet.

[20]  Philippe Van De Borne,et al.  Guidelines for the management of arterial hypertension , 2014 .

[21]  E. O’Brien,et al.  Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. , 1997, Lancet.

[22]  Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group. , 1991, JAMA.